Balancing the benefits and risks of two doses of Dabigatran compared with Warfarin in Atrial Fibrillation ONLINE FIRST

Atrial Fibrillation Friday, June 21st, 2013

JACC: June 1, 2013

Objective  The primary objective was to compare the net clinical benefit of dabigatran 110mg bid and 150mg bid with that of warfarin in patients with atrial fibrillation (AF).

Background  In patients with AF, dabigatran 110mg bid and 150mg bid are associated with similar rates of death. However, the higher dose reduces ischemic stroke and increases bleeding compared with the lower dose. Therefore, there is uncertainty about how to evaluate the overall benefit of the two doses.

Methods  In 18,113 AF patients in RE-LY, we used a previously developed method for integrating ischemic and bleeding events as “ischemic stroke equivalents” in order to compare a weighted benefit of two doses of dabigatran with each other, and with that of warfarin.  Read more

National Minority Quality Forum Clinical Trial Engagement Network Map Childhood Obesity MapHIV Z-Atlas: Peripheral Arterial Disease Atlas Map Lung Cancer Index Z-Atlas: Chronic Kidney Disease AFIB Index Cardiometabolic Health Aliance Minority Diabetes Coalition U.S. Diabetes Index County Edition U.S. Diabetes Index Research Edition Medicare Index Medicare Index Stroke Edition About The Minority Stroke Working Group Hepatitis C Disease Index Lead Risk Index Map MRSA StrokePAD Minority Index The South Texas Diabetes Initiative Minority Stroke Consortium YouTube NMQF Videos IPAB Action Center National Health Index

© 2011 National Minority Quality Forum, Inc. All Rights Reserved.